<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215835</url>
  </required_header>
  <id_info>
    <org_study_id>letrozole pretreatment</org_study_id>
    <nct_id>NCT04215835</nct_id>
  </id_info>
  <brief_title>Letrozole Pretreatment With Misoprostol Induction of Abortion In First-Trimester Missed Miscarriage</brief_title>
  <official_title>Letrozole Pretreatment With Misoprostol for Induction of Abortion In First-Trimester Missed Miscarriage Among Women With One or More Previous Cesarean Deliveries.: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the success rate of letrozole and misoprostol versus misoprostol alone
      for medical termination of first-trimester pregnancy among women with one or more previous
      cesarean deliveries.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 5, 2020</start_date>
  <completion_date type="Anticipated">April 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>induction to abortion time</measure>
    <time_frame>6 hours</time_frame>
    <description>induction to abortion time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of complete miscarriage</measure>
    <time_frame>6 hours</time_frame>
    <description>Incidence of complete miscarriage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for surgical evacuation of the products of conception</measure>
    <time_frame>6 hours</time_frame>
    <description>Need for surgical evacuation of the products of conception</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Missed Abortion</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets of Letrozole 2.5 mg will be given as single daily dose, 7.5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum two doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>three tablets of placebo will be given as a single daily dose, for two days at home and will be admitted on day 3 and continue treatment with misoprostol 800 mcg every three hours up to maximum two doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole then misoprostol</intervention_name>
    <description>Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days
Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo then misoprostol</intervention_name>
    <description>Drug: Placebo placebo for 3 days
Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age less than 64 days gestation (&lt;9 wks).

          -  Hemoglobin &gt;10 g/dL.

          -  BMI between 18.5 kg/m2 and 25 kg/m2.

          -  Missed abortion.

          -  previous one or more cesarean delivaries

        Exclusion Criteria:

          -  Molar pregnancy.

          -  Fibroid uterus.

          -  Uterine anomalies.

          -  Coagulopathy.

          -  Medical disorder that contraindicate induction of abortion (e.g. heart failure).

          -  Previous attempts for induction of abortion in the current pregnancy.

          -  Allergy to misoprostol or letrozole.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AHMED SAMY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AHMED SAMY</last_name>
    <phone>+201100681167</phone>
    <email>ahmedsamy8233@gmail.com</email>
  </overall_contact>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Samy aly ashour</investigator_full_name>
    <investigator_title>assistant professor obstetrics and gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Abortion, Missed</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

